Moving Targets in Hepatocellular Carcinoma: Hepatic Progenitor Cells as Novel Targets for Tyrosine Kinase Inhibitors

Gastroenterology

Volumn 135, Issue 3, 2008, Pages 733-735

  Siegel, Abby ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CD133 ANTIGEN; CD45 ANTIGEN; ERLOTINIB; IMATINIB; PLACEBO; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; SORAFENIB; STEM CELL FACTOR; SUNITINIB; THY 1 ANTIGEN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER STEM CELL; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; FLUID RETENTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER REGENERATION; LIVER TOXICITY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; RISK REDUCTION; SIDE EFFECT;

EID: 51249099399     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.07.036     Document Type: Editorial

References (25)

1. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 5 Suppl 1 (2004) S27-S34
2. Schwartz M., Roayaie S., and Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 4 (2007) 424-432
3. Siegel A.B., McBride R.B., El-Serag H.B., et al. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol 103 (2008) 120-127
4. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
5. Thomas M.B., and Abbruzzese J.L. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23 (2005) 8093-8108
6. Llovet J., Ricci S., Mazzaferro V., et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial) (2007) Proceedings of the American Society of Clinical Oncology meeting, Chicago, IL, June 1-5; 18S
7. Thomas M.B., Chadha R., Iwasaki K., et al. The combination of bevacizumab and erlotinib shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). Proceedings of the American Society of Clinical Oncology meeting, Chicago, IL, June 1-5 (2007) 4567
8. Zhu A.X., Sahani D.V., Tomaso E.D., et al. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): insights from a multidisciplinary phase II study. Proceedings of the American Society of Clinical Oncology meeting, Chicago, IL, May 30-June 3 (2008)
9. Siegel A.B., Cohen E.I., Ocean A., et al. A phase II trial evaluating the clinical and biological effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26 (2008) 2992-2998
10. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
11. Becker G., Schmitt-Graeff A., Ertelt V., et al. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol) 19 (2007) 204-208
12. Chung C.Y., Yeh K.T., Hsu N.C., et al. Expression of c-kit protooncogene in human hepatocellular carcinoma. Cancer Lett 217 (2005) 231-236
13. Bergers G., Song S., Meyer-Morse N., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111 (2003) 1287-1295
14. Campbell J.S., Johnson M.M., Bauer R.L., et al. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation 75 (2007) 843-852
15. Knight B., Tirnitz-Parker J., and Olynyk J. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. Gastroenterology 135 (2008) 969-979
16. Lim R., Knight B., Patel K., et al. Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. Hepatology 43 (2006) 1074-1083
17. Sell S., and Leffert H.L. Liver cancer stem cells. J Clin Oncol 26 (2008) 2800-2805
18. Tsamandas A.C., Syrokosta I., Thomopoulos K., et al. Potential role of hepatic progenitor cells expression in cases of chronic hepatitis C and their relation to response to therapy: a clinicopathologic study. Liver Int 26 (2006) 817-826
19. Lin A.Y., Fisher G.A., So S., et al. Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol 31 (2008) 84-88
20. Eckel F., von Delius S., Mayr M., et al. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 69 (2005) 363-371
21. Ma S., Chan K.W., Hu L., et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132 (2007) 2542-2556
22. + cancer stem cells in human liver cancer. Cancer Cell 13 (2008) 153-166
23. Yang Z.F., Ngai P., Ho D.W., et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 47 (2008) 919-928
24. Lee J.S., Heo J., Libbrecht L., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12 (2006) 410-416
25. Hortobagyi G.N. Trastuzumab in the treatment of breast cancer. N Engl J Med 353 (2005) 1734-1736